Showing results (31-40 of 283) with videos related to
Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among VeteransMichael S Wolf, Karen A Fitzner, Eowyn F Powell, et al.Cancer Journal (Sudbury, Mass.)|September 26, 2025
Mitigating the Impact of Drug Shortages in Oncology: Lessons Learned From the 2023 Shortages of Carboplatin and CisplatinMaxwell L Izen, June M McKoy, Linda Martin, et al.Cancer Journal (Sudbury, Mass.)|September 26, 2025
Cancer Drugs and United States Tariffs: Attention Must Be PaidMaxwell L Izen, June M McKoy, Linda Martin, et al.Best Practice & Research. Clinical Haematology|March 29, 2005
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) groupAndrew M Evens, Charles L Bennett, Stefano LuminariExpert Opinion on Drug Safety|August 24, 2016
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promiseTerhi Hermanson, Charles L Bennett, Iain C MacdougallCancer Journal (Sudbury, Mass.)|September 26, 2025
National Stockpiling of Pediatric Cancer Medications in the United States: An Alternative Approach to Hospital-Based Storage for Essential Oncology DrugsMaxwell L Izen, Mia Lynch, Charles L BennettThe American Journal of Managed Care|February 22, 2023
Humira: the first $20 billion drugJason B Gibbons, Micaela Laber, Charles L BennettPlos One|September 25, 2024
A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseasesCharles L Bennett, Joseph Magagnoli, Krishna Gundabolu, et al.Cancer Treatment and Research|November 30, 2022
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse ReactionsSumimasa Nagai, Bartlett Witherspoon, Chadi Nabhan, et al.Expert Opinion on Drug Safety|May 5, 2020
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et alAndrew C Bennett, Charles L Bennett, Bartlett J WitherspoonPageof 29